Indeed, simultaneous targeted inhibition of RAF/MEK/ERK with the combination of sorafenib and statins are known to induce potentiated effects in different tumor cell lines, inducing cell cycle arrest and apoptosis [25]. The gene discussed is RAF1; the disease is neoplasm.